Testing effectiveness (Phase 2)Ended earlyNCT01832857What this trial is testingPhase 2 Safety, Tolerability and Efficacy Study of CPI-613 in Cancer PatientsWho this might be right forCancer Cornerstone Pharmaceuticals 7